Growth factor receptors as molecular targets for cancer diagnosis and therapy.
Growth factor receptors are of great interest as molecular targets for the diagnosis and treatment of cancer. Growth factor receptors are frequently over expressed on malignant cell populations since many cellular oncogenes encode either growth factors or their receptors. The wild-type epidermal growth factor receptor has a molecular weight of 170 kD and is over expressed on gliomas, bladder tumors, squamous cells carcinomas and breast carcinomas. Another growth factor oncogene, c-erbB-2, encodes a 185-kD glycoprotein found on the surface of gliomas, breast and ovarian cancers as well as other carcinomas of epithelial origin. In addition to causing over expression, oncogenic transformation also can result in genomic re-arrangements. An important example from the perspective of targeting is EGFRvIII, a deletion mutant which lacks amino acids 6-273 in the extracellular domain of the epidermal growth factor receptor. The EGFRvIII molecule (145 kD) may be of great value for targeting because it appears to be tumor-specific. Antibodies have been developed with specific reactivity with these growth factor receptors. Since these antibodies are internalized into the cell after receptor binding, it is necessary to use radiolabeling methods which residualize the radioactivity in the tumor cell after intracellular catabolism. To investigate this problem, we have evaluated the effect of radioiodination method on the in vitro and in vivo properties of an anti-EGFRvIII antibody. Methods studied were Iodogen, tyramine-cellobiose, and N-succinimidyl 5-iodo-3-pyridine-carboxylate with the last offering optimal localization in a human xenograft model.
Zalutsky
M R
MR
Department of Radiology, Duke University Medical Center, Durham, NC 27710, USA.
D000818:Animals; D000911:Antibodies, Monoclonal; D066246:ErbB Receptors / Q000032:analysis / Q000235:genetics; D006801:Humans; D007457:Iodine Radioisotopes; D051379:Mice; D009369:Neoplasms / Q000175:diagnosis* / Q000378:metabolism / Q000628:therapy*; D017354:Point Mutation; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis
D000911:Antibodies, Monoclonal; D066246:ErbB Receptors; D007457:Iodine Radioisotopes; D018719:Erb-b2 Receptor Tyrosine Kinases